Opicapone, a once daily COMT inhibitor, was licensed in Europe in 2016 and the United States in 2020 as an adjunctive drug to l‐dopa in patients with Parkinson's disease and end‐of‐dose motor fluctuations.7, 8, 9. Here, COMT is linked to Parkinson disease.